Story thread · 8 reports / 5 sources
Alumis downgraded at Guggenheim after trial setback for SLE candidate
seekingalpha.com · 11d
How the coverage leans
Across 5 sources · syndicated copies counted once
First report: Alumis stock tumbles 55% after lupus drug trial misses goals — investing.com, 13d
The coverage
- Alumis’ TYK2 drug fails in key lupus study
biopharmadive.com · 13d
- Alumis' TYK2 drug fails in lupus trial; CEO sees 'clear path forward'
endpts.com · 13d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.